
The Dish’s Weekly Biotechnology News Wrap Up – March 25, 2016
Cell Culture Events
Webinars:
Novel Lipid Supplement, Cell Ess, Increases Antibody Production in CHO Cells for Industrial Manufacturing Applications
Webinar Description:
Enhancing protein production is a common bioproduction goal. Cell Ess, when used to supplement to an optimized cell and media system, resulted in a 37% increase in productivity per cell. Used as a 5% feed, it resulted in a 25% increase in yield and extension of peak protein production. Our results suggest that an increase in protein production may not require a change in the metabolic state of the cells.
Learning Objectives:
- How a novel media supplement for large scale bioproduction was used to significantly boost mAb protein yield as a continuous feed in a previously optimized system.
- That the supplement works in a scalable fashion from shaker flask to wave bag bioreactor
- How one can increase protein yield without increasing biomass, i.e. fewer cells become more efficient producing the engineered protein of interest.
Who Should Attend:
- Those in early development of bioproduction of proteins in eukaryotic cells
- Those in media optimization or yield optimization for scaled bioproduction of proteins
- Department Directors, Program Directors, Project leaders, involved in optimization of large scale bioproduction of proteins.
Speaker:
Dr. Adam Elhofy, Ph.D., CSO, Essential Pharmaceuticals
Dr Elhofy developed the core technology for the Ess line of products and aided in creating patents around novel uses of materials. Dr. Elhofy has over 14 years of scientific research experience in the areas of immunology, neuroscience, and oncology. He was funded by both the National Institutes of Health and the Multiple Sclerosis society as an investigator at Northwestern University Medical School. His doctoral research won him the award of the Top 5 trainee scientists by the American Association of Immunologists. Dr. Elhofy has 14 scientific publications in peer reviewed journals. He has played a variety of roles with start-up biotech companies ranging from Principal Investigator to Director of Corporate Development.
Be in or be out: continuous processing of biopharmaceutical proteins
FREE webinar with live Q&A session Wednesday 30 March 2016 Presented by Günter Jagschies Senior Director Strategic Customer Relations GE Healthcare Günter’s experience from the bioprocessing industry stretches over more than 30 years. He has held senior management positions at GE Healthcare in Sales, Marketing, and R&D. In 2012, he received the BioProcess International Award as “Thought Leader of the Decade”, for Downstream Processing. Continuous processing from cell culture through to drug substance offers numerous advantages compared with a process based on batch unit operations. Floor space requirements in classified areas can be significantly reduced; the cost load in equipment is much lower as many unit operations can be down-sized; and the product quality can be improved when a process is run in steady-state. Furthermore, continuous processing can enable production of proteins that are unstable, toxic, or difficult to express. On the downside, the risk profile of a long running time with extended requirements for cell line and equipment stability, potential contamination or other reasons for failure can be considered higher. Finally, the cost of goods sold for batch processes in today’s biomanufacturing environment is decreasing to low double digit USD levels per gram. How does this fact affect the case for continuous processing? Join us for this one hour webinar and learn about:- The next-generation biomanufacturing facilities.
- Insight into current state of continuous processing and predictions for the future.
- Pros and cons for continuous processing.
- Innovations such as periodic counter-current chromatography, which drive the adoption of continuous downstream processing.
Bioprocess Insights Webinar Series:
Upstream – How to Improve Productivity and Process Economy Through Intensified Seed Train Strategies
Wed, Apr 20, 2016 – Time:11:00 AM EDT – Duration:30 minutes Dr. Andreas Castan will discuss the upstream seed train and will show how a process intensification strategy can be used to compress timelines and decrease the cost for this unit operation. Register Now.